Annual Meeting 2014: Panorama 1 Phase 3 study of PAN or placebo plus BTZ and Dex in RRMM

Annual Meeting 2014: Panorama 1 Phase 3 study of PAN or placebo plus BTZ and Dex in RRMM

545 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Paul Richardson, MD
Dana-Farber Cancer Institute
Boston, Massachusetts, USA

Panorama 1: A randomized, double-blind, phase 3 study of panobinostat or placebo plus bortezomib and dexamethasone in relapsed or relapsed and refractory multiple myeloma

Panobinostat (PAN) is a potent pan-deacetylase inhibitor that demonstrates synergistic antimyeloma activity when combined with bortezomib (BTZ) + dexamethasone (Dex). Early studies demonstrated durable responses in patients (pts) with relapsed (Rel) and relapsed/refractory (RR) multiple myeloma (MM) treated with PAN + BTZ + Dex. This initiated the PANORAMA 1 study, presented herein.

Visit our website at: http://www.myeloma.org
Up Next Autoplay